Avidity Biosciences Inc.

30.50
-3.33 (-9.84%)
At close: Mar 18, 2025, 3:59 PM
30.63
0.43%
After-hours: Mar 18, 2025, 07:42 PM EDT
-9.84%
Bid 30.58
Market Cap 3.67B
Revenue (ttm) 10.19M
Net Income (ttm) -301.52M
EPS (ttm) -2.89
PE Ratio (ttm) -10.55
Forward PE -10.01
Analyst Buy
Ask 31.03
Volume 1,145,836
Avg. Volume (20D) 1,347,991
Open 34.07
Previous Close 33.83
Day's Range 30.47 - 34.07
52-Week Range 21.56 - 56.00
Beta 1.02

About RNA

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to tr...

Industry Biotechnology
Sector Healthcare
IPO Date Jun 12, 2020
Employees 391
Stock Exchange NASDAQ
Ticker Symbol RNA
Full Company Profile

Analyst Forecast

According to 13 analyst ratings, the average rating for RNA stock is "Buy." The 12-month stock price forecast is $66, which is an increase of 116.43% from the latest price.

Stock Forecasts

Next Earnings Release

Avidity Biosciences Inc. is scheduled to release its earnings on May 8, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
6 days ago
+10.24%
Avidity Biosciences shares are trading higher afte... Unlock content with Pro Subscription
4 months ago
+12.35%
Avidity Biosciences shares are trading higher. Needham reiterated a Buy rating on the stock.